



20th February, 2025

The Secretary,
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400 001
Scrip Code: 544250

The Secretary,
The National Stock Exchange of India Limited
C-1, Block G, Exchange Plaza
Bandra-Kurla Complex
Bandra East, Mumbai - 400 050
Symbol: SANOFICONR

Sub.: Outcome of the Board Meeting held on Thursday, 20th February, 2025

Dear Sir/Ma'am,

We refer to our letter dated 14th February 2025, informing you of our Board Meeting that was scheduled today. In this regard, we wish to inform you that pursuant to Regulation 30 and 33 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Board of Directors at its meeting held today i.e., Thursday, 20th February 2025, *inter-alia* transacted the following:

1. Approved the Audited Standalone Financial Statements of the Company for the Quarter and Financial Year ended 31st December 2024. Accordingly, we enclose a copy of the Audited Standalone Financial Statements and Auditor's Report for the Financial Year ended 31st December, 2024 along with Statement of Assets and Liabilities as on that date and Standalone Statement of Cashflows for the year ended 31st December, 2024 as **Annexure A**

Extract of the aforesaid results will be published in the newspapers in the format prescribed under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The aforesaid financial results will also be available on the website of the Company (www.sanofi.in)

Further, pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare that the Statutory Auditors of the Company, M/s Kalyaniwalla & Mistry LLP have issued the Audit Report with unmodified opinion for the Financial Year ended 31st December 2024.

2. Recommended a final dividend of Rs. 55/- per equity share having face value of Rs.10/- each for the Financial Year ended 31st December 2024, subject to approval by shareholders of the Company at the ensuing Annual General Meeting (AGM). The Company shall inform in due course the record date / book closure for payment of dividend.
3. Considered and approved the re-appointment of M/s. Kishore Bhatia & Associates, Cost Accountants as Cost Auditor of the Company for Cost Audit for the year ending 31st December 2025 and approve the remuneration to be paid subject to ratification of the shareholders. A brief Profile of M/s. Kishore Bhatia & Associates, in terms of SEBI Circular dated July 13, 2023, is annexed herewith as **Annexure B**



4. Considered and approved appointment of M/s. BNP Associates & Co., Company Secretaries, as the Secretarial Auditor of the Company for the period of 5 years commencing from 1st January 2025 and to fix their remuneration. A brief Profile of M/s. BNP Associates & Co., Company Secretaries, in terms of SEBI Circular dated July 13, 2023, is annexed herewith as **Annexure C**

The meeting of Board of Directors commenced at 04:00 p.m. and concluded at 5:40 p.m.

Kindly take the above information on record.

Thanking you,

Yours faithfully,

For **Sanofi Consumer Healthcare India Limited**

Nikunj Kumar Savaliya
Company Secretary and Compliance Officer
Membership No.: FCS 7048

KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

INDEPENDENT AUDITOR'S REPORT

TO THE BOARD OF DIRECTORS OF SANOFI CONSUMER HEALTHCARE INDIA LIMITED

Report on the Audit of the Financial Results

Opinion

We have audited the accompanying Annual Financial Results of **Sanofi Consumer Healthcare India Limited** (“the Company”) for the year ended December 31, 2024, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (“SEBI”) (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“LODR Regulations”).

In our opinion and to the best of our information and according to the explanations given to us, these financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the LODR Regulations in this regard; and
- ii. gives a true and fair view in conformity with the applicable accounting standards (“Ind AS”) and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information for the year ended December 31, 2024.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (“SAs”) specified under section 143(10) of the Companies Act, 2013 (“the Act”). Our responsibilities under those Standards are further described in the *Auditor’s Responsibilities for the Audit of the Financial Results* section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (“the ICAI”) together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Board of Director’s Responsibilities for the Financial Results

These financial results have been prepared on the basis of the annual financial statements. The Company’s Board of Directors are responsible for the preparation and presentation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001
TEL.: (91) (22) 6158 6200, 6158 7200 FAX : (91) (22) 6158 6275

In preparing the financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

- i. In accordance with the Scheme of Arrangement ("the Scheme") between Sanofi India Limited (SIL) and its shareholders, creditors and Sanofi Consumer Healthcare India Limited (SCHIL), duly approved by the Hon'ble National Company Law Tribunal, Mumbai Bench, by an order dated May 07, 2024 and filed with Registrar of Companies on June 01, 2024, the Consumer Healthcare Business, along with its related assets and liabilities at the values appearing in the books of account of SIL as on the close of business hours as on May 31, 2024, was demerged, transferred and vested into the Company with effect from June 01, 2024. The appointed date and effective date of the Scheme was June 01, 2023, and June 01, 2024, respectively. Upto May 31, 2024, the business was run by SIL in trust for SCHIL and risks associated with the business remains with SCHIL from date of business transfer.

As per the requirement of Appendix C to Ind AS 103 – Business Combinations:

- a) the financials for the previous period are drawn from May 10, 2023, being the date of incorporation, accordingly, the financials for the previous period ended December 31, 2023, are from May 10, 2023, to December 31, 2023, and were carved out from the audited financial statements of SIL and have been accounted by the Management in respect of the Consumer Healthcare Business after considering the adjustments to give effect to the Scheme and accordingly, are not comparable with the figures for the current year.
- b) for the period May 10, 2023, to May 31, 2024, the transactions of the Consumer Healthcare Business were carried out by Sanofi India Limited (SIL) in trust on behalf of the Company, in accordance with the Scheme of Arrangement.

In accordance with the Scheme, the Company has recognized in its books of account, the carrying amount of assets aggregating to Rs. 3,648 million and liabilities aggregating to Rs. 1,746 million as on May 31, 2024, pertaining to the Consumer Healthcare Business transferred from SIL. The excess of the carrying amount of assets transferred over the carrying amount of liabilities and profit earned from May 10, 2023, to May 31, 2024, aggregating to Rs. 1,902 million (including capital reserve of Rs. 407 million) and net of dividend paid by SIL in trust on behalf of the Company amounting to Rs. 1,152 million has been credited to reserves in accordance with the Scheme as on May 31, 2024.

- ii. The previous year financial statements have been audited by a firm of Chartered Accountants other than Kalyaniwalla & Mistry LLP, which have been restated as per the requirements of Appendix C to Ind AS 103 – Business Combinations, to give effect to the Scheme of Arrangement.
- iii. The figures for the quarters ended December 31, of the respective financial years as reported in these financial results are the balancing figures between the audited figures in respect of the full financial year ended December 31 and the published year to date figures up to the end of the third quarter of the relevant financial year. The figures up to the end of the third quarter have only been reviewed and not subjected to an audit.

Our opinion on these financial results is not modified in respect of the above matters.

For KALYANIWALLA & MISTRY LLP
CHARTERED ACCOUNTANTS
Firm Registration No. 104607W / W100166

Sai Venkata Ramana Damarla
Partner
Membership. No. 107017
UDIN: 25107017BMLFOL5908
Place: Mumbai
Dated: February 20, 2025.

Sanofi Consumer Healthcare India Limited

Registered Office : Unit 1104, 11th Floor, Godrej Two Pirojshanagar, Eastern Express Highway, Vikhroli East, Mumbai, Maharashtra, India, 400079

Corporate Identity Number: U21002MH2023PLC402652

Tel no: (91-22) 45288555

Website: www.sanofi.in Email: igrc.schil@sanofi.com

STATEMENT OF AUDITED FINANCIAL RESULTS FOR YEAR ENDED DECEMBER 31, 2024

Particulars	₹ in Million				
	Quarter ended 31.12.2024 (Unaudited) Refer note: 10	Quarter ended 30.09.2024 (Unaudited)	Quarter ended 31.12.2023 (Unaudited) Refer note: 3 & 10	Year ended 31.12.2024 (Audited) Refer note: 3	Period ended 31.12.2023 (Audited) wef 10.05.23 - 31.12.2023 Refer note: 3
1. Revenue from Operations	1,707	1,599	2,246	7,245	5,554
2. Other Income	50	42	26	130	41
3. Total Income (1+2)	1,757	1,641	2,272	7,375	5,595
4. Expenses					
(a) Cost of Materials Consumed	148	141	552	1,274	1,364
(b) Purchases of stock in trade	184	144	68	421	200
(c) Changes in Inventories of work-in-progress, stock-in-trade and finished goods	87	102	(11)	166	(45)
(d) Employee benefits expense	276	274	194	1,027	544
(e) Finance costs	4	34	-	39	-
(f) Depreciation and amortisation expense	10	15	7	45	18
(g) Other expenses	391	307	548	1,651	1,303
Total Expenses	1,100	1,017	1,358	4,623	3,384
5. Profit before exceptional items and tax (3-4)	657	624	914	2,752	2,211
6. Exceptional items (Refer notes 6 & 7)	(29)	(12)	(18)	(284)	(18)
7. Profit before tax (5+6)	628	612	896	2,468	2,193
8. Tax expense					
Current Tax	176	169	234	696	563
Deferred Tax	9	(7)	(17)	(38)	(19)
9. Profit for the period /year (7-8)	443	450	679	1,810	1,649
10. Other comprehensive income (OCI)					
Items that will not be reclassified to the statement of profit and loss					
- Remeasurements of post-employment benefit obligations	(19)	-	-	(19)	-
- Income Tax impact relating to these items	5	-	-	5	-
11. Total comprehensive income for the period/year (9+10)	429	450	679	1,796	1,649
12. Paid-up equity share capital (Face Value of ₹ 10 per share)	230	230	20	230	20
13. Share capital pending for allotment (Face Value of ₹ 10 per share)	-	-	230	-	230
14. Other equity	-	-	-	2,500	1,826
15. Basic and diluted earnings per share (not annualised) (in ₹)	19.25	19.52	29.48	78.59	71.60

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with our LODR Regulations Audit Report dated February 20, 2025.

Sanofi Consumer Healthcare India Limited
STATEMENT OF ASSETS AND LIABILITIES

₹ in Million

Particulars	As at December 31, 2024 (Audited) Refer note: 3	As at December 31, 2023 (Audited) Refer note: 3
ASSETS		
Non-current assets		
Property, plant and equipment	97	20
Capital work in progress	7	-
Right-of-use assets	175	-
Intangible assets	19	29
Intangible assets under development	-	26
Financial assets		
Other financial assets	36	8
Deferred tax assets (net)	62	19
Total non-current assets	396	102
Current assets		
Inventories	409	966
Financial assets		
(i) Trade receivables	137	316
(ii) Cash and cash equivalents	3,269	16
(iii) Loans	6	5
(iv) Other financial assets	38	2,048
Other current assets	58	1
Total current assets	3,917	3,352
TOTAL ASSETS	4,313	3,454
EQUITY AND LIABILITIES		
Equity		
Equity share capital	230	20
Share pending issuance	-	230
Other equity		
Reserves and Surplus	2,500	1,826
Total equity	2,730	2,076
LIABILITIES		
Non-current liabilities		
Financial liabilities		
Lease liabilities	166	-
Employee benefit obligations	111	79
Total non-current liabilities	277	79
Current liabilities		
Financial liabilities		
(i) Lease liabilities	37	-
(ii) Trade payables		
(a) Total outstanding dues of micro enterprises and small enterprises	33	76
(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	670	524
Employee Benefit Obligations	244	129
Other current liabilities	141	-
Provisions	178	49
Current tax liabilities (net)	3	521
	1,306	1,299
Total current liabilities	1,583	1,378
TOTAL EQUITY AND LIABILITIES	4,313	3,454

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with our LODR Regulations Audit Report dated February 20, 2025.

Sanofi Consumer Healthcare India Limited
STATEMENT OF CASH FLOWS FOR THE YEAR ENDED DECEMBER 31, 2024

₹ in Million

Particulars	Year ended December 31, 2024 Audited	Year ended December 31, 2023 Audited
Cash flows from Operating activities	2,468	2,193
Profit before tax		
Adjustment for :		
Depreciation and amortization expenses	45	18
Unrealised exchange (gain)	(1)	-
Finance costs	39	-
Interest income	(118)	(40)
Share based payment	10	-
Provision for bad and doubtful debts (net)	1	-
Impairment on Intangible Asset Under development classified under exceptional item	29	-
Operating profit before working capital changes	2,473	2,171
Adjustments for (increase) / decrease in operating assets		
Non-current financial assets	(28)	-
Inventories	557	(42)
Trade receivables	179	(3)
Current financial assets	2,010	(2,053)
Loans	(1)	-
Other current assets	(57)	(1)
Adjustments for increase / (decrease) in operating liabilities		
Employee benefit obligations	128	(41)
Trade payables	103	116
Other current liabilities & provisions	270	(109)
Cash generated from operations	5,634	38
Taxes paid (net of refunds)	(1,244)	(42)
Net Cash inflow / (outflow) from Operating activities (A)	4,390	(4)
Cash flows from Investing activities		
Interest received	118	40
Purchase of property, plant and equipment and Intangible assets including Capital work-in-progress	(99)	(40)
Net cash inflow from Investing activities (B)	19	-
Cash flows from financing activities		
Issue of Share Capital	-	20
Interest paid on lease	(4)	-
Dividend paid (Refer note 3 and 4)	(1,152)	-
Net cash used in financing activities (C)	(1,156)	20
Net increase in cash and cash equivalents (A+B+C)	3,253	16
Cash and Cash Equivalents at the beginning of the year/period	16	-
Cash and Cash Equivalents at the end of the year/period	3,269	16
Non- cash financing and investing activities (D)		
Acquisition of Right-of-use assets	198	
Components of Cash and Cash Equivalents		
Cash and Cash Equivalents at the end of the year/period	3,269	16

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with our LODR Regulations Audit Report dated February 20, 2025.

Notes:

1. These audited financial results have been prepared in accordance with recognition and measurement principles of the Indian Accounting Standards ("Ind AS"), as prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and the other accounting principles generally accepted in India.
2. The statutory auditors have issued audit report with unmodified conclusion on the above audited financial results for the quarter and year ended December 31, 2024. The audited financial results which are published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee in their meeting held on February 20, 2025, and approved by the Board of Directors of the Company at its meeting held on February 20, 2025.
3. The Board of Sanofi India Limited (SIL) on May 10, 2023, had approved a Scheme of Arrangement under Sections 230 to 232 of the Companies Act, 2013 ("Scheme"), to demerge the Consumer Healthcare business of Sanofi India Limited into its wholly owned subsidiary Sanofi Consumer Healthcare India Limited ("SCHIL"). In accordance with the Scheme of Arrangement between Sanofi India Limited and its shareholders and creditors and SCHIL ("the Scheme") as approved by the Hon'ble National Company Law Tribunal, Mumbai Bench by an order dated May 7, 2024, the Consumer Healthcare Business, along with its related assets and liabilities at the values appearing in the books of accounts of SIL on the close of business hours as on May 10, 2023 (Incorporation Date), was demerged, transferred and vested into the Company with effect from May 10, 2023 as set out in Appendix C of Ind AS 103 'Business Combinations'. The appointed date and effective date of the Scheme was June 1, 2023 and June 1, 2024 respectively, however, financials are drawn from May 10, 2023 as per the requirement of Ind AS 103. Business was run by SIL in trust for SCHIL and risk associated with the business remains with SCHIL from date of business transfer. Accordingly, the previous year results and results for the year ended December 2023 are from May 10, 2023, to December 31, 2023, and not comparable with current year quarter and the year ended December 2024.
4. Pursuant to the demerger, the Company has recognized in its books of account, the carrying amount of assets and liabilities as on May 31, 2024, pertaining to the Consumer Healthcare business transferred from SIL. The excess of the carrying amount of assets transferred over the carrying amount of liabilities transferred and profit earned from May 10, 2023 to May 31, 2024 aggregating to ₹ 1,902 million (including capital reserve of ₹407 million) and net of dividend paid by SIL in trust on behalf of the Company amounting to ₹ 1,152 million has been credited to reserves in accordance with the Scheme as on May 31, 2024.
5. The record date, for determining the eligibility of the shareholders of SIL for allotting shares of the SCHIL in the ratio of 1 (One) fully paid-up new equity share of ₹ 10 each of the Company for every 1 (One) equity share of ₹ 10 each of SIL (pursuant to the Scheme of Arrangement) was fixed as June 13, 2024. Accordingly, the Company has allotted 23,030,622 shares amounting to ₹ 230 million (adjusted against Capital Reserve) to the eligible shareholders of SIL on June 25, 2024.
6. Company had voluntarily decided to recall Allegra Suspension and Combiflam Suspension as precautionary measure from distributors, hospitals, and retailers on July 19, 2024. Earlier, Company recalled Depura Adult and Depura Kids produced by the same manufacturer. The recall of the products is substantially completed from distributors and it is expected to receive minor returns from retailers by June 2025. The Company has taken a decision to temporarily suspend manufacturing of aforesaid products to review and streamline the manufacturing and quality processes at the third-party manufacturer engaged in manufacturing. Quality is paramount to the Company and the endeavor is to bring back the products to the market as soon as possible. Our non-recalled portfolio continues to perform strongly in the market.
7. Exceptional items for the year ended December 31, 2024, amounts to ₹ 284 million which includes product recall related cost towards Sales return and inventory write off ₹ 108 million, expenses towards listing formalities amounting to ₹ 77 million, demerger expenses amounting to ₹ 70 million and Intangible asset under development written off amounting to ₹ 29 million, which was acquired under the Scheme of Arrangement (Refer Note :3) based on the internal assessment done by the company of its recoverability. (Previous period ended December 31, 2023: ₹ 18 million which is towards demerger expenses).
8. The Board has recommended a final dividend of ₹ 55 per equity share of ₹ 10 for the year ended December 31, 2024, which would be paid after approval of shareholders at the ensuing Annual General Meeting of the Company.
9. The Company has a single business segment namely 'Pharmaceutical Business'.

10. The figures for the quarter ended December 31, 2024 and December 31, 2023 are the balancing figures between audited figures in respect of the full financial year up to December 31, 2024 and December 31, 2023 and the unaudited published year-to-date figures up to September 30, 2024 and September 30, 2023 respectively, which were subject to a limited review, being the date of the end of the third quarter of the said financial year.
11. The Company listed its equity shares with the National Stock Exchange of India Limited (“NSE”) and the BSE Limited (“BSE”) on September 13, 2024.
12. There is a change of Holding Company from ‘Hoechst GmbH and Sanofi S.A. to ‘Opella Healthcare Participations BV’ in October 2024. However, Sanofi S.A remains the ultimate Holding Company.
13. The Company does not have any subsidiary, associates or joint ventures as on December 31, 2024.

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with our LODR Regulations Audit Report dated February 20, 2025.

SANOFI CONSUMER HEALTHCARE INDIA LIMITED

February 20, 2025

Himanshu Bakshi
Managing Director
DIN: 08188412

Annexure B

Information as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated July13, 2023

Sr. No.	Particulars	Remark
1	Name of Auditor	M/s. Kishore Bhatia & Associates
2	Reason for change viz. re appointment	Re-Appointment of M/s. Kishore Bhatia & Associates Cost Auditor of the Company
3	Date of appointment	February 20, 2025
4	Term of appointment	Financial Year 2025
5	Brief Profile	M/s. Kishore Bhatia & Associates have been present in the accounting & financial field for more than three decades. They believe in 'substance over style' and have been delivering top of the line quality output to the clients. They also believe in adhering to the work schedules and delivering the work within the time committed.

Annexure C

Information as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated July 13, 2023

Sr. No.	Particulars	Remark
1	Name of Auditor	M/s. BNP Associates & Co.
2	Reason for change viz. re appointment	Appointment of M/s. BNP Associates & Co. Secretarial Auditor of the Company
3	Date of appointment	February 20, 2025
4	Term of appointment	Financial Year commencing from 1 st January, 2025
5	Brief Profile	BNP & Associates [BNP] is a firm of Practicing Company Secretaries registered with The Institute of Company Secretaries of India, New Delhi with Mr. B. Narasimhan, Mr. Avinash Bagul, and Mr. Ramaswami Kalidas, Senior Company Secretaries, as Partners. All three of them have diverse exposure in the areas of corporate advisory services, transactional services, litigation, advocacy and legal due diligence. Moreover, the firm also has Associate Partners with rich profiles, as detailed hereunder, and they also share the values as that of the firm i.e., Character, Competence and Commitment.